| Autor: |
Leal, B., Rodrigues, D., Carvalho, C., Ferreira, R., Chaves, J.M.M., Bettencourt, A., Freitas, J., Lopes, J. M.C.F., Ramalheira, J.E.D.P., Martins da Silva, A., Costa, P.P., Martins da Silva, B. |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Popis: |
Background and aims: Several experimental and clinical studies have suggested that microRNAs (miRNAs) could be potential epilepsy biomarkers. Nowadays, research has been focused in miR-134, a brain-specific miRNA that plays important roles in dendritic spine development and neuronal structure regulation. An upregulation of miR-134 has been reported both in brain tissue of experimental models (Jimenez-Mateos 2012) and plasma from epileptic patients (Sun 2017). It has also been observed that some anti-seizure drugs down regulate mir-134 plasmatic levels (Sun 2017) highlighting the role of this miRNA in epileptogenesis. Our aim was to quantify miR-134 serum levels in a cohort of Mesial Temporal Lobe Epilepsy (MTLE) patients and correlate with clinical characteristics such as drug response. info:eu-repo/semantics/publishedVersion |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
